Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Unknown 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Diarrhea 1Carcinoma, Medullary 1

Interventions

pembrolizumab 1019Carboplatin 959Paclitaxel 932Gemcitabine 793Cisplatin 748Docetaxel 682Bevacizumab 610Pemetrexed 502Nivolumab 486Cyclophosphamide 466Capecitabine 461Fluorouracil 417Dexamethasone 402Rituximab 372Oxaliplatin 347Injections 342atezolizumab 297Trastuzumab 297Leucovorin 286Cetuximab 282Irinotecan 266130-nm albumin-bound paclitaxel 252Prednisone 244Doxorubicin 240Ipilimumab 226Lenalidomide 220Fulvestrant 217fludarabine 214durvalumab 205Erlotinib Hydrochloride 188

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Interventional × Calcium Aluminosilicate × Clear all
NCT01739634 2012-12-03

The Efficacy of CASAD in Patients With Diarrhea Related to Medullary Thyroid Cancer

Salient Pharmaceuticals Incorporated

Phase 1/2 Unknown
10 enrolled

Diarrhea, Carcinoma, Medullary

Data powered by HemOnc (CC BY 4.0) Colophon âš¡